|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 753.93 USD | -0.21% |
|
-2.79% | -2.32% |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Biological Products | ||||||||||
Discovery, Development, and Commercialization of Medicines for Serious Diseases | 16.07B | 12.17B | 13.12B | 14.2B | 14.34B | |||||
Total Assets | 25.43B | 29.21B | 33.08B | 37.76B | 40.56B | |||||
Interest Expense | -57.3M | -59.4M | -73M | -55.2M | -43.8M | |||||
Income Tax Expense | 1.25B | 520M | 246M | 367M | 726M | |||||
CAPEX | -552M | -1.62B | -719M | -756M | -898M | |||||
EBT | 9.33B | 4.86B | 4.2B | 4.78B | 5.23B | |||||
D&A | 286M | 341M | 421M | 483M | 544M | |||||
Operating Income | 8.95B | 4.74B | 4.05B | 3.99B | 3.58B | |||||
Net Income | 8.08B | 4.34B | 3.95B | 4.41B | 4.5B |
Geographical Revenue Distribution History
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Rest of World (ROW) | - | - | - | - | - | |||||
United States | - | - | - | - | - | |||||
Total Assets | 2.68B | 2.96B | 3.38B | 3.88B | 4.33B | |||||
Total Assets | 798M | 803M | 771M | 716M | 788M |
- Stock Market
- Equities
- REGN Stock
- Financials Regeneron Pharmaceuticals, Inc.
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
